Free Access
Med Sci (Paris)
Volume 25, Number 8-9, Août-Septembre 2009
Page(s) 719 - 726
Section M/S revues
Published online 15 August 2009
  1. Smith W. The structural and functional plasticity of influenza virus. Lancet 1951; 1 : 885–91. [Google Scholar]
  2. Nguyen-Van-Tam JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine 2003; 21 : 1762–8. [Google Scholar]
  3. Bean WJ, Schell M, Katz J, et al. Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. J Virol 1992; 66 : 1129–38. [Google Scholar]
  4. Treanor J, Kawaoka Y, Miller R, Webster RG, Murphy B. Nucleotide sequence of the avian influenza A/Mallard/NY/6750/78 virus polymerase genes. Virus Res 1989; 14 : 257–69. [Google Scholar]
  5. Kawaoka Y, Krauss S, Webster RG. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 1989; 63 : 4603–8. [Google Scholar]
  6. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009 (online). [Google Scholar]
  7. Peiris JS, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 2007; 20 : 243–67. [Google Scholar]
  8. Tam JS. Influenza A (H5N1) in Hong Kong: an overview. Vaccine 2002; 20 (suppl 2) : S77–81. [Google Scholar]
  9. Tran TH, Nguyen TL, Nguyen TD, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004; 350 : 1179–88. [Google Scholar]
  10. Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006; 355 : 2186–94. [Google Scholar]
  11. Smallman-Raynor M, Cliff AD. Avian influenza A (H5N1) age distribution in humans. Emerg Infect Dis 2007; 13 : 510–2. [Google Scholar]
  12. Novel swine-origin influenza A (H1N1) virus investigation team. Emergence of a novel swine-origin influenza A (H1N1) Virus in Humans. N Engl J Med 2009 (online). [Google Scholar]
  13. Treanor JJ. Influenza virus. In : Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett’s. Principles and practice of infectious diseases, 6th ed. Philadelphia : Elsevier Churchill Livingstone,2005 : 2060–78. [Google Scholar]
  14. Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982; 4 : 25–44. [Google Scholar]
  15. Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine 2008 (suppl 4) : D35–40. [Google Scholar]
  16. Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza. Recommendations of the advisory committee on immunization practices (ACIP), 2007. MMWR Recomm Rep 2007;56 (RR-6) : 1–54. [Google Scholar]
  17. Hehme N, Engelmann H, Kuenzel W, et al. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004; 103 : 163–71. [Google Scholar]
  18. Stephenson I, Wood JM, Nicholson KG, et al. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103 : 91–5. [Google Scholar]
  19. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005; 11 : 1515–21. [Google Scholar]
  20. Al-Azemi A, Bahl J, Al-Zenki S, et al. Avian influenza A virus (H5N1) outbreaks, Kuwait, 2007. Emerg Infect Dis 2008; 14 : 958–61. [Google Scholar]
  21. Smith GJ, Fan XH, Wang J, et al. Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci USA 2006; 103 : 16936–41. [Google Scholar]
  22. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004; 25 : 98–104. [Google Scholar]
  23. Fedson DS, Dunnill P. From scarcity to abundance: pandemic vaccines and other agents for have not countries. J Public Health Policy 2007; 28 : 322–40. [Google Scholar]
  24. Leroux-Roels I, Leourx-Roels G. Current status and progress of prepandemic and pandemic influenza vaccine developement. Expert Rev Vaccines 2009; 8 : 401–23. [Google Scholar]
  25. Kiey MP, Subbarao K. The pandemic influenza vaccine challenge. Vaccine 2008; 26S (suppl 4) : D3-D4. [Google Scholar]
  26. Kenney RT, Frech SA, Muenz LR, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351 : 2295–301. [Google Scholar]
  27. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004 25 ; 351 : 2286–94. [Google Scholar]
  28. Jefferson TO, Rivetti D, Di Pietrantoni C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007; 2 : CD001269. [Google Scholar]
  29. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354 : 1343–51. [Google Scholar]
  30. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367 : 1657–64. [Google Scholar]
  31. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368 : 991–7. [Google Scholar]
  32. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370 : 580–9. [Google Scholar]
  33. Levie K, Leroux-Roels I, Hoppenbrouwers K, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008 : 642–9. [Google Scholar]
  34. Wu J, Fang HH, Chen JT, et al. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 2009; 8 : 1087–95. [Google Scholar]
  35. Leroux-Roels I, Benrhard R, Gerard P, et al. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008; 3 : e1665. [Google Scholar]
  36. Suguitan AL Jr, McAuliffe J, Mills KL, et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006; 3 : e360. [Google Scholar]
  37. Laddy DJ, Yan J, Corbitt N, et al. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 2007; 25 : 2984–9. [Google Scholar]
  38. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191 : 1210–5. [Google Scholar]
  39. Mozdzanowska K, Zharikova D, Cudic M, et al. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 2007; 4 : 118. [Google Scholar]
  40. Zharikova D, Mozdzanowska K, Feng J, et al. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 2005; 79 : 6644–54. [Google Scholar]
  41. Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature 2006; 442 : 448–52. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.